Serum amyloid A regulates TLR2/4-mediated IFN-β signaling pathway against Marek's disease virus

Area of Science:

• Immunology
• Virology
• Molecular Biology

Background:

• Serum amyloid A (SAA) is an acute phase protein vital for innate immunity against pathogens.
• Marek's disease virus (MDV), an oncogenic alphaherpesvirus, triggers innate immune responses, including SAA activation.
• The precise role and mechanism of SAA in MDV infection remain uncharacterized.

Purpose of the Study:

• To elucidate the pathway through which SAA exerts its anti-MDV function.
• To investigate SAA's role in MDV-induced innate immunity.
• To determine if SAA can inhibit MDV replication.

Main Methods:

• In vivo and in vitro experiments measuring SAA expression during MDV infection.
• SAA overexpression and knockdown studies to assess its effect on MDV replication.
• Analysis of Toll-Like Receptor 2/4 (TLR2/4), Interferon Beta (IFN-β), and Interferon regulatory factor 7 (IRF7) promoter activities.
• Assessment of type I Interferon (IFN-I) and interferon-stimulated genes (ISGs) expression.
• Utilizing a TLR2/4 inhibitor (OxPAPC) to validate the pathway.

Main Results:

• MDV infection significantly increased SAA expression both in vivo and in vitro.
• SAA overexpression inhibited MDV replication, while SAA knockdown enhanced it.
• SAA activated TLR2/4-mediated promoter activity for IFN-β and IRF7.
• SAA boosted TLR2/4-mediated IFN-β signal transduction, increasing IFN-I and ISG mRNA levels.
• Inhibition of TLR2/4 by OxPAPC blocked the anti-MDV effects of SAA.

Conclusions:

• SAA effectively inhibits MDV replication through the TLR2/4-mediated IFN-β signaling pathway.
• This pathway enhances the expression of type I Interferons and interferon-stimulated genes.
• This study reveals a novel mechanism for SAA in combating oncogenic herpesviruses.
• Findings offer new perspectives on controlling herpesvirus infections using acute phase proteins.